Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors

Journal of Nuclear Medicine

Volumn 44, Issue 1, 2003, Pages 1-6

  Buscombe, John R ^a   Caplin, Martyn E ^a   Hilson, Andrew J W ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

111In pentetreotide; Efficacy; Neuroendocrine; Therapy; Toxicity

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; PENTETREOTIDE IN 111;

ABDOMINAL CRAMP; ADULT; AGED; ARTICLE; CANCER MORTALITY; CARCINOID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; FLUSHING; FOLLOW UP; GASTRINOMA; GLUCAGONOMA; HUMAN; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; RADIATION DOSE; SURVIVAL TIME; THYROID MEDULLARY CARCINOMA; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, NEUROENDOCRINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RADIATION INJURIES; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SOMATOSTATIN; SURVIVAL RATE; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 0037225303     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Reubi JC, Laissue J, Krenning E, Lamberts SWJ. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol. 1992;43:27-35.
2. Krenning EP, Bakker EP, Breenman WAP, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;333: 242-244.
3. Jamar F, Fiasse R, Leners N, Pauwels S. Somatastatin imaging with indium-111 pentetreotide in gastrenteropancreatic neuroendocrine tumours; safety, efficacy and impact on patient management. J Nucl Med. 1995;36:542-549.
4. Ramage JK, Williams R, Buxton-Thomas M. Imaging secondary neuroendocrine tumours of the liver: comparison of I123 metaiodobenzylguanidine (MIBG) and In111-labelled octreotide (Octreoscan). Quart J Nucl Med. 1996;89:539-542.
5. Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H, Beijnen JH. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol. 1996; 14:1829-1838.
6. Oberg K. The use of chemotherapy in the management of neuroendocrine tumors. Endocrinol Metab Clin North Am. 1993;22:941-952.
7. Caplin ME, Buscombe JR, Hilson AL, Jones AL, Watkinson AF, Burroughs AK Carcinoid tumour. Lancet. 1998;352:799-805.
8. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol. 1999;94:1381-1387.
9. Kim YH, Ajani JA, Carrasco CH, et al. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest 1999;17:474-478.
10. Andersson P, Forssell-Aronsson E, Johanson V, et al. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111 DTPA-D-Phe1-octreotide. J Nucl Med. 1996;37:2002-2006.
11. 1]-octreotide: a case history. Ann NY Acad Sci. 1994;733:496-506.
12. 111In-pentetreotide: initial observations and future directions. Cancer J Sci Am. 1998;4:84-102.
13. Caplin ME, Mielcarek W, Buscombe JR, et al. Toxicity of high activity In-111-octreotide therapy in patients with disseminated neuroendocrine tumours. Nucl Med Commun. 2000;21:97-102.
14. Gehan EA, Tefft MC. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst. 2000;92:179-181.
15. 111In-labeled somatostatin analogs for tumour scintigraphy and radionuclide therapy. Cancer Res. 1998;58:437-441.
16. de Jong M, Breeman WA, Bernard HF, et al. Therapy of neuroendocrine tumors with radiolabeled somatostatin analogues. Quart J Nucl Med. 1999;43:356-366.
17. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439-1447.
18. Herskovic A, Orton C, Seyedsadr M, et al. Initial experience with a practical hyperfractionated accelerated radiotherapy regimen. Int J Radiat Oncol Biol Phys. 1991;21:1275-1281.
19. Stabin MG, Kooil PPM, Bakker WH, et al. Radiation dosimetry for indium-111 pentetreotide. J Nucl Med. 1997;38:1919-1922.
20. 131I-CC49 in colorectal cancer. Cancer. 1994;73(3 suppl):1057-1066.
21. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190:432-445.